Sophiris Bio Inc. (SPHS) Stock Price Down 6.3%
Sophiris Bio Inc. (NASDAQ:SPHS)’s share price dropped 6.3% during mid-day trading on Monday . The company traded as low as $4.60 and last traded at $4.73, with a volume of 1,200,152 shares traded. The stock had previously closed at $5.05.
SPHS has been the subject of a number of recent research reports. Maxim Group upped their target price on Sophiris Bio from $4.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, August 10th. Echelon Wealth Partners reaffirmed a “buy” rating and issued a $5.00 target price on shares of Sophiris Bio in a report on Friday, June 10th.
The stock’s market capitalization is $89.72 million. The stock has a 50-day moving average price of $3.96 and a 200 day moving average price of $2.13.
Sophiris Bio (NASDAQ:SPHS) last posted its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.06. Equities analysts forecast that Sophiris Bio Inc. will post ($0.69) earnings per share for the current year.
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).